BioLargo Assigned Federal and Military Supply System National Stock Number
SANTA ANA, CA --
- Opens recurring sales channels for health care related products -
- Establishes working capital line of credit to support sales efforts -
BioLargo, Inc. (OTCQB: BLGO) announced its subsidiary Odor-No-More, Inc. was assigned National Stock Numbers (NSNs) for multiple products by the Defense Logistics Information Service (DLIS), allowing the U.S. military, and federal and civil agencies, to order these products as a stock item directly from the company. The NSNs were assigned for the company's six body fluid solidifiers.
Dennis Calvert, BioLargo's president, stated: 'The NSN assignment is a significant milestone as it establishes an important sales channel for these products, as well as provides a pathway for introducing additional products. NSNs are officially recognized by the United States government, the North Atlantic Treaty Organization (NATO) and many governments around the world. In addition, NSNs are assigned for products frequently reordered by the military and other agencies, representing a significant long-term market opportunity for BioLargo. This sales channel is particularly well suited for our advanced wound care products in development by our subsidiary Clyra Medical Technologies. Due to the potential of this market and our multiple product applications within the military channel, we have established a small working capital line of credit to complement our cash on hand to support our increased sales efforts.'
The company's body fluid solidifiers are used to solidify bodily fluids evacuated during surgery, in hospital settings and military deployment situations. Using BioLargo's advanced iodine technology, the products provide advanced holding power, increased safety, and superior odor control in an easy to use mechanism that requires no special handling.
'Our products went through a comprehensive evaluation process by healthcare providers in multiple Military Medical Facilities (MMFs), after which the product received positive reviews and was suggested for NSN assignment by the U.S. Army. This validation reflects the traction we expect these products will gain in markets outside the military channel as well,' concluded Calvert.
Downeast Logistics, a certified Service-Disabled Veteran-Owned Small Business (SDVOSB) with 13 years in operations, helped organize this sales channel and also supports BioLargo as a distribution partner to facilitate its expanding sales initiatives within its Odor-No-More subsidiary. Downeast Logistics' designation as a SDVOSB places it within a group of highly sought after vendors to the US government.
About BioLargo, Inc.
BioLargo, Inc. (OTCQB: BLGO) makes life better by delivering technology-based products that help solve some of the world's most important problems that threaten water, food, agriculture, healthcare and energy. More information can be found about the company and its subsidiaries at www.BioLargo.com. The subsidiary BioLargo Water, Inc. (www.BioLargoWater.com) showcases the Advanced Oxidation Systems, including its AOS Filter, a product in development specifically designed to eliminate common, troublesome, and dangerous (toxic) contaminants in water in a fraction of the time and cost of current technologies. BioLargo also owns a 50% interest in the Isan System, which was honored with a 'Top 50 Water Company for the 21st Century' award by the Artemis Project. The subsidiary Odor-No-More Inc., features award-winning products serving the pet, equine, and consumer markets, including the Nature's Best Solution® and Deodorall® brands. (www.OdorNoMore.com). The subsidiary Clyra Medical Technologies, Inc. (www.ClyraMedical.com), focuses on advanced wound care management and is preparing to make FDA 510(k) applications in 2014.
Safe Harbor Statement
The statements contained herein, which are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, the risks and uncertainties included in BioLargo's current and future filings with the Securities and Exchange Commission, including those set forth in BioLargo's Annual Report on Form 10-K for the year ended December 31, 2012.
Related news
-
U.S. FDA approves Xarelto to treat venous thromboembolism (VTE) and to prevent VTE in children
Xarelto is the only Factor Xa anticoagulant FDA approved for pediatric patients and offers a flexible weight-based dosing Xarelto is available in both oral tablet and liquid suspension formulations for use in appropriate children less than 18 years of age Convenient liquid formulation advances standard of care for children; alleviates administration challenges found with injectable alternatives The U.S. Food and Drug Administration (FDA) has approved two pediatric indications for Xarelto (rivaroxaban): the...
-
Phase III trial with Nubeqa (darolutamide) in combination with docetaxel and androgen deprivation therapy meets primary endpoint of significantly increasing overall survival in patients with metastatic hormone-sensitive prostate cancer
ARASENS trial demonstrates an increase in overall survival evaluating darolutamide in combination with docetaxel and androgen deprivation therapy (ADT) compared to docetaxel and ADT, a standard of care in metastatic hormone-sensitive prostate cancer (mHSPC) / Bayer plans to present these pivotal data at a forthcoming scientific congress and to discuss them with health authorities / ARASENS is part of broad development program for darolutamide which includes another ongoing Phase III trial in mHSPC, ARANOTE,...
-
InspireMD Receives Reimbursement Approval for CGuard™ Embolic Prevention System from the French National Authority for Health
InspireMD, Inc. (Nasdaq: NSPR), a global developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD) and stroke prevention, today announced that its CGuard EPS stent system has received a positive opinion from the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDIMTS) of the French National Authority for Health (HAS) regarding reimbursement in France, and the CGuard EPS is being added to the list of reimbursed...
-
IFEMA MADRID will host the Congress of the European Association for Cranio Maxillo Facial Surgery in the Palacio Municipal
This biennial congress comes to Madrid as the Spanish Professor Julio Acero occupies the Presidency of the Association, and it expects to host more than 2.000 attendees from 70 countries. This edition will mean the return to the face-to-face format after the last appointment of the Congress, celebrated in Munich in 2018, and the virtual edition celebrated last summer after the impossibility of holding it in person in Paris in 2020. IFEMA MADRID continues working for the reactivation of the MICE sector in...
-
Artugen Announces Five Abstracts Published in the 30th ECCMID Abstract Book
Clostridioides difficile infection (CDI) causes the most common healthcare-associated infections in the United States and the most frequent hospital-acquired intestinal infection in Europe and worldwide. The prevalence of C. difficile outbreaks since the early 2000s has resulted in higher morbidity and mortality along with increasing medical costs throughout the world. Without effective antibiotics and therapeutics for the prevention and treatment of infections, many of the achievements of modern medicine such...
Customer comments
No comments were found for BioLargo Assigned Federal and Military Supply System National Stock Number. Be the first to comment!